Bioresorbable Vascular Scaffold Korean Expert Panel Report.
- Author:
Jung Min AHN
1
;
Duk Woo PARK
;
Sung Jin HONG
;
Young Keun AHN
;
Joo Yong HAHN
;
Won Jang KIM
;
Soon Jun HONG
;
Chang Wook NAM
;
Do Yoon KANG
;
Seung Yul LEE
;
Woo Jung CHUN
;
Jung Ho HEO
;
Deok Kyu CHO
;
Jin Won KIM
;
Sung Ho HER
;
Sang Wook KIM
;
Sang Yong YOO
;
Myeong Ki HONG
;
Seung Jea TAHK
;
Kee Sik KIM
;
Moo Hyun KIM
;
Yangsoo JANG
;
Seung Jung PARK
Author Information
- Publication Type:Review
- Keywords: Coronary disease; Bioresorbable vascular scaffold; Stents; Thrombosis
- MeSH: Coronary Disease; Drug Liberation; Drug-Eluting Stents; Humans; Korea; Stents; Thrombosis
- From:Korean Circulation Journal 2017;47(6):795-810
- CountryRepublic of Korea
- Language:English
- Abstract: Bioresorbable vascular scaffold (BRS) is an innovative device that provides structural support and drug release to prevent early recoil or restenosis, and then degrades into nontoxic compounds to avoid late complications related with metallic drug-eluting stents (DESs). BRS has several putative advantages. However, recent randomized trials and registry studies raised clinical concerns about the safety and efficacy of first generation BRS. In addition, the general guidance for the optimal practice with BRS has not been suggested due to limited long-term clinical data in Korea. To address the safety and efficacy of BRS, we reviewed the clinical evidence of BRS implantation, and suggested the appropriate criteria for patient and lesion selection, scaffold implantation technique, and management.
